Efficacy of ivabradin in combined treatment of patients with postinfarction systolic chronic cardiac failure

  • Authors: Potapenko A.V.1, Abdulazizov O.S.1, Dyachuk L.I.1, Kiyakbaev G.K.1, Kobalava Z.D.1, Moiseev V.S.1, Potapenko AV2, Abdulazizov OS.2, Dyachuk LI3, Kiyakbaev GK2, Kobalava Z.D2, Moiseev VS2
  • Affiliations:
    1. Russian University of Peoples' Friendship, Moscow
    2. City Hospital N 64, Moscow
  • Issue: Vol 83, No 12 (2011)
  • Pages: 19-26
  • Section: Articles
  • URL: https://ter-arkhiv.ru/0040-3660/article/view/30930
  • Cite item

Abstract


Aim. To study effects of ivabradin on clinicohemodynamic and prognostic parameters in patients after myocardial infarction (MI) with systolic chronic cardiac failure (SCCF).
Material and methods. A population-based randomized prospective trial enrolled 49 patients (40 males - 81,6%, mean age 63,1 ± 8,1 years) with sinus rhythm and a longer than 3 month history of MI. The patients were randomized into 2 groups: 23 patients of group 1 received standard treatment plus ivabradin, 26 patients of group 2 received standard treatment alone. Follow-up was 36,1 ± 6,2 months. We analysed the trend in heart rate (HR), blood pressure (BP), parameters of echocardiography, ECG, levels of electrolytes, creatinin in blood plasma, frequency of hospitalizations, recurrent non-fatal MI and lethality (combined end point). Results. In the end of the trial ivabradin significantly decreased HR from 71 to 64 b/m. Frequency of combined end point of efficacy was 30,4 and 50% in group 1 and 2, respectively. In group 1 primary end point in high baseline HR occurred more frequently than in HR < 70 b/m in 6 (50%) and 1 (9,1%) cases, respectively, but these differences were not significant (p = 0,068). In group 2 the differences were significant - 9 (90%) and 4 (25%) cases, respectively (p = 0,004). By none of the parameters of ECG, plasma electrolytes, creatinine level significant intergroup differences were found. Conclusion. In the same trend in BP and ECG, group 1 patients showed significant and more pronounced HR lowering than group 2 patients. Addition of ivabradin to standard treatment of SCCF after MI promoted less frequency of hospitalizations, recurrent non-fatal MI, fatal cardiovascular events. This effect was especially strong in high baseline HR.

About the authors

Anton Valer'evich Potapenko

Email: medicol@rambler.ru

Olimzhon Sharifzhanovich Abdulazizov

Email: alimjan007@mail.ru

Larisa Ivanovna Dyachuk

Email: Cardio-Heart@yandex.ru

Gayrat Kaluevich Kiyakbaev

Email: gayratk@rambler.ru

Zhanna Davidovna Kobalava

Email: zkobalava@mail.ru

Valentin Sergeevich Moiseev

Email: vmoiseev37@mail.ru

A V Potapenko

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

O Sh Abdulazizov

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

L I Dyachuk

City Hospital N 64, Moscow

City Hospital N 64, Moscow

G K Kiyakbaev

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

Zh D Kobalava

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

V S Moiseev

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

References

  1. Buch P., Rasmussen S., Gislason G. H. et al. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 2007; 93: 210-215.
  2. Eagle K. A., Lim M. J., Dabbous O. H. et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. J. A. M. A. 2004; 291: 2727-2733.
  3. Burns R. J., Gibbons R. J., Yi Q. et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol. 2002; 39: 30-36.
  4. Borer J. S. Heart rate: from risk marker to risk factor. Eur. Heart J. 2008; 10 (Suppl. F): F2-F6.
  5. Fox K., Borer J. S., Camm A. J. et al. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 2007; 50: 823-830.
  6. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart. J. 2007; 28: 2375-2414.
  7. Diaz A., Bourassa M. G., Guertin M. C., Tardif J. C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart. J. 2005; 26: 967-974.
  8. Kolloch R., Legler U. F., Champion A. et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/ trandolapril Study (INVEST). Eur. Heart. J. 2008; 29: 1327- 1334.
  9. Di Francesco D., Camm A. J. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-1765.
  10. Joannides R., Moore N., Iacob M. et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br. J. Clin. Pharmacol. 2006; 61: 127-137.
  11. Manz M., Reuter M., Lauck G. et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
  12. Camm A. J., Lau C. P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs. 2003; 4: 83-89.
  13. Borer J. S., Fox K., Jaillon P., Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-823.
  14. Ruzyllo W., Ford I., Tendera M. et al. Antianginal and antiischemic affects of the I(f) current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multi-center trial. Eur. Heart J. 2004; 25: Abstr. 878.
  15. Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur. Heart J. 2004; 25: Abstr. 876.
  16. Tardif J. C., Ford I., Tendera M. et al. On behalf of INITIATIVE study investigators group. Antianginal and anti-ischemic effects of the I(f) current inhibitor ivabradine compared to atenolol as monotherapies in patients with chronic stable angina. Eur. Heart J. 2003; 24: Abstr. 186.
  17. Tardif J.-C., Ponikowski P., Kahan Th. for the ASSOCIATE study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 2009; 30 (5): 540-548.
  18. Fox K., Garcia M. A. A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27 (11): 1341-1381.
  19. Рекомендации по диагностике и лечению стабильной стенокардии. М.: ВНОК; 2008.
  20. Fox K., Ford I., Steg P. G. et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.
  21. Fox K., Ford I., Steg Ph. G. et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart. J. 2009; 30: 2337-2345.
  22. Guth B. D., Indolfi C., Heusch G. et al. Mechanisms of benefit in the ischemic myocardium due to heart rate reduction. Basic Res. Cardiol. 1990; 85 (Suppl. 1): 157-166.
  23. Beere P., Glagov S., Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-182.
  24. Pocock S. J., Wang D., Pfeffer M. A. et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart. J. 2006; 27: 65-75.
  25. Fox K., Ford I., Steg P. G. et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trail. Lancer 2008; 372 (9641): 817-821.
  26. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur. Heart J. 2007; 28: 3012-3019.
  27. CIBIS-II Investigators and Committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
  28. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in 60. Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
  29. Packer M., Bristow М. R., Cohn J. N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996; 334: 1349-1355.
  30. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981; 304: 801- 807.
  31. Lechat P. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-1433.
  32. McAlister F. A., Wiebe N., Ezekowitz J. A. et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 2009: 150: 784-794.
  33. Komajda M., Follath E., Swedberg K. et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 2003; 24: 464-474.
  34. Dickstein K., Cohen-Solal A., Fjlippatos G. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart. J. 2008; 29: 2388-2442.
  35. Национальные рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр). Сердеч. недостат. 2010; 11 (1): 57 с.
  36. Goldberger J. J., Bonow R. O., Cuffe M. et al. for the PАСЕ-MI investigators. β-blocker use following myocardial infarction: Low prevalence of evidence-based dosing. Am. Heart. J. 2010; 160: 435-442.
  37. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 2010; 376: 875-885.
  38. Teerlink J. Ivabradine in heart failure - no paradigm SHIFT...yet. Lancet 2010; 376, 847-849.
  39. Васюк Ю. А., Школьник Е. Л., Лебедев Е. В. Возможноети ингибитора If-каналов ивабрадина в комплексном лечении больных стабильной стенокардией, перенесших инфаркт миокарда. Кардиология. 2010; 5: 13-18.

Statistics

Views

Abstract - 30

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies